Medikit Co.,Ltd. (TYO:7749)
Japan · Delayed Price · Currency is JPY 2,895.00
+5.00 (0.17%)
Aug 25, 2026, 1:40 PM JST
Medikit Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 4,512 | 4,659 | 4,775 | 4,291 | 4,472 |
Depreciation & Amortization | 2,038 | 1,689 | 1,544 | 1,323 | 1,269 |
Loss (Gain) From Sale of Assets | -27 | - | 3 | 11 | 25 |
Loss (Gain) From Sale of Investments | - | - | 4 | - | 50 |
Other Operating Activities | -1,649 | -1,591 | -1,509 | -1,036 | -1,090 |
Change in Accounts Receivable | -48 | 360 | 402 | -686 | -130 |
Change in Inventory | -880 | -362 | -593 | 348 | 48 |
Change in Accounts Payable | -322 | 113 | 158 | 366 | -56 |
Change in Other Net Operating Assets | 1,110 | -1,307 | 50 | -137 | -1,435 |
Operating Cash Flow | 4,734 | 3,561 | 4,834 | 4,480 | 3,153 |
Operating Cash Flow Growth | 32.94% | -26.33% | 7.90% | 42.09% | -13.12% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -3,441 | -3,817 | -1,688 | -983 | -1,779 |
Sale of Property, Plant & Equipment | 39 | 1 | 9 | 20 | 38 |
Cash Acquisitions | - | - | -632 | -2,557 | - |
Sale (Purchase) of Intangibles | -41 | -32 | -17 | -42 | -5 |
Investment in Securities | 2,149 | -6 | 5,494 | -10 | -5 |
Other Investing Activities | 1 | -13 | 64 | -10 | 32 |
Investing Cash Flow | -1,293 | -3,870 | 3,230 | -3,582 | -1,719 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Repurchase of Common Stock | -410 | -550 | -4,832 | - | -66 |
Common Dividends Paid | -1,408 | -1,328 | -1,751 | -1,509 | -834 |
Other Financing Activities | -3 | -1 | -1 | - | -1 |
Financing Cash Flow | -1,821 | -1,879 | -6,584 | -1,509 | -901 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | -26 | 69 | 37 | 86 | 94 |
Miscellaneous Cash Flow Adjustments | -1 | 67 | 1 | - | -1 |
Net Cash Flow | 1,593 | -2,052 | 1,518 | -525 | 626 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 1,293 | -256 | 3,146 | 3,497 | 1,374 |
Free Cash Flow Growth | - | - | -10.04% | 154.51% | -34.35% |
Free Cash Flow Margin | 5.44% | -1.14% | 14.40% | 16.18% | 6.83% |
Free Cash Flow Per Share | 88.77 | -17.38 | 192.64 | 208.35 | 81.78 |
Levered Free Cash Flow | -209 | 276.38 | 3,506 | 2,963 | 2,213 |
Unlevered Free Cash Flow | -204.63 | 280.75 | 3,510 | 2,967 | 2,217 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 7 | 7 | 7 | 6 | 7 |
Cash Income Tax Paid | 1,646 | 1,588 | 1,590 | 1,036 | 1,091 |
Change in Working Capital | -140 | -1,196 | 17 | -109 | -1,573 |